CL2019002244A1 - Variantes de pertuzumab y su evaluación. (divisional solicitud 201702445) - Google Patents
Variantes de pertuzumab y su evaluación. (divisional solicitud 201702445)Info
- Publication number
- CL2019002244A1 CL2019002244A1 CL2019002244A CL2019002244A CL2019002244A1 CL 2019002244 A1 CL2019002244 A1 CL 2019002244A1 CL 2019002244 A CL2019002244 A CL 2019002244A CL 2019002244 A CL2019002244 A CL 2019002244A CL 2019002244 A1 CL2019002244 A1 CL 2019002244A1
- Authority
- CL
- Chile
- Prior art keywords
- pertuzumab
- variants
- compositions
- evaluation
- species
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44704—Details; Accessories
- G01N27/44747—Composition of gel or of carrier mixture
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dispersion Chemistry (AREA)
- Electrochemistry (AREA)
- Peptides Or Proteins (AREA)
Abstract
LA PRESENTE SOLICITUD DESCRIBE VARIANTES DE PERTUZUMAB. EN PARTICULAR, SE REVELA: UNA VARIANTE DE CISTEÍNA NO APAREADA QUE COMPRENDE CISTEÍNAS Cys23/Cys88 NO APAREADAS EN UNO O AMBOS DOMINIOS VARIABLES LIVIANAS DE PERTUZUMAB, UNA VARIANTE AFUCOSILADA DE PERTUZUMAB, UNA ESPECIE DE BAJO PESO MOLECULAR (LMWS) DE PERTUZUMAB, Y UNA ESPECIE DE ELEVADO PESO MOLECULAR (HMWS) DE PERTUZUMAB. LA SOLICITUD DESCRIBE ADEMÁS LAS VARIANTES AISLADAS, COMPOSICIONES, COMPOSICIONES FARMACÉUTICAS, Y ARTÍCULOS DE FABRICACIÓN QUE COMPRENDEN LAS VARIANTES, ASÍ COMO TAMBIÉN MÉTODOS PARA PREPARAR Y CARACTERIZAR LAS VARIANTES Y SUS COMPOSICIONES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361812603P | 2013-04-16 | 2013-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019002244A1 true CL2019002244A1 (es) | 2019-11-29 |
Family
ID=50694078
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2015003049A CL2015003049A1 (es) | 2013-04-16 | 2015-10-15 | Variantes de pertuzumab y su evaluación |
CL2017002445A CL2017002445A1 (es) | 2013-04-16 | 2017-09-28 | Variantes de pertuzumab y su evaluación. |
CL2019002244A CL2019002244A1 (es) | 2013-04-16 | 2019-08-08 | Variantes de pertuzumab y su evaluación. (divisional solicitud 201702445) |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2015003049A CL2015003049A1 (es) | 2013-04-16 | 2015-10-15 | Variantes de pertuzumab y su evaluación |
CL2017002445A CL2017002445A1 (es) | 2013-04-16 | 2017-09-28 | Variantes de pertuzumab y su evaluación. |
Country Status (25)
Country | Link |
---|---|
US (7) | US9815904B2 (es) |
EP (2) | EP2986643A2 (es) |
JP (2) | JP2016522176A (es) |
KR (2) | KR20200085942A (es) |
CN (1) | CN105121471A (es) |
AR (1) | AR095863A1 (es) |
AU (3) | AU2014254086B2 (es) |
BR (1) | BR112015024926A2 (es) |
CA (2) | CA2907776C (es) |
CL (3) | CL2015003049A1 (es) |
CR (1) | CR20150576A (es) |
EA (1) | EA201591643A1 (es) |
HK (1) | HK1211948A1 (es) |
IL (2) | IL241103B (es) |
MA (1) | MA38567A1 (es) |
MX (2) | MX368259B (es) |
MY (1) | MY173295A (es) |
NZ (2) | NZ751877A (es) |
PE (2) | PE20211214A1 (es) |
PH (1) | PH12015502382A1 (es) |
RU (2) | RU2019115089A (es) |
SG (3) | SG10201911353WA (es) |
TW (1) | TWI554284B (es) |
WO (1) | WO2014172371A2 (es) |
ZA (1) | ZA201506594B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
PL2493922T3 (pl) | 2009-10-26 | 2017-07-31 | F.Hoffmann-La Roche Ag | Sposób wytwarzania glikozylowanych immunoglobulin |
NZ751877A (en) | 2013-04-16 | 2020-04-24 | Genentech Inc | Pertuzumab variants and evaluation thereof |
TW201827077A (zh) * | 2016-12-28 | 2018-08-01 | 美商建南德克公司 | 晚期her2表現癌症之治療 |
SI3570884T1 (sl) | 2017-01-17 | 2021-02-26 | Genentech, Inc. | Subkutane formulacije protiteles HER2 |
US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
EP3615695A1 (en) * | 2017-04-24 | 2020-03-04 | Genentech, Inc. | Erbb2/her2 mutations in the transmebrane or juxtamembrane domain |
US20200271663A1 (en) * | 2017-09-13 | 2020-08-27 | Mayo Foundation For Medical Education And Research | Identification and monitoring of acid hydrolysis products of immunoglobulin heavy chains |
JP7259778B2 (ja) | 2020-01-31 | 2023-04-18 | トヨタ自動車株式会社 | 車両、及び自動運転システム |
CN113189184B (zh) * | 2021-04-28 | 2022-09-09 | 浙江大学 | 含有半胱氨酸的毛细管凝胶电泳样品缓冲液 |
TW202309045A (zh) | 2021-04-29 | 2023-03-01 | 大陸商上海匯連生物醫藥有限公司 | 抗體偶聯藥的製備方法及應用 |
KR102511384B1 (ko) | 2022-04-14 | 2023-03-16 | 지용환 | 곡물의 손상을 줄일 수 있는 도정기 |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3587657D1 (de) | 1984-01-30 | 1993-12-23 | Imp Cancer Res Tech | Verbesserungen an wachstumsfaktoren. |
US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
ES2106033T3 (es) | 1989-05-19 | 1997-11-01 | Genentech Inc | Dominio extracelular de her2. |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
DE69739673D1 (de) | 1996-11-27 | 2009-12-31 | Genentech Inc | Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix |
US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
CA2324494A1 (en) | 1998-03-27 | 1999-09-30 | Genentech, Inc. | Apo-2 ligand-anti-her-2 antibody synergism |
SI1308455T1 (sl) | 1998-05-06 | 2006-08-31 | Genentech Inc | Sestavek, ki obsega protitelesa anti-HER2 |
US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
ES2320311T3 (es) | 1999-05-14 | 2009-05-21 | Genentech, Inc. | Tratamiento con anticuerpos anti-erbb2. |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
BR0012195A (pt) | 1999-06-25 | 2002-07-23 | Genentech Inc | Método para tratar câncer de próstata num ser humano, artigo de fabricação e uso de um anticorpo que liga erbb2 |
US6627196B1 (en) | 1999-08-27 | 2003-09-30 | Genentech, Inc. | Dosages for treatment with anti-ErbB2 antibodies |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
KR101135233B1 (ko) | 2000-05-19 | 2012-04-12 | 제넨테크, 인크. | ErbB 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석 |
US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
AU2002256971B2 (en) | 2000-12-28 | 2008-04-03 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
DK1501856T3 (da) | 2002-04-10 | 2013-03-25 | Genentech Inc | Anti-HER2 antistofvarianter |
PT2263691E (pt) | 2002-07-15 | 2012-11-12 | Hoffmann La Roche | Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4) |
SI1543038T2 (sl) | 2002-09-11 | 2020-12-31 | Genentech, Inc. | Čiščenje proteinov |
JP2006516117A (ja) | 2002-11-21 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 抗ErbB2抗体を用いた非悪性疾病または疾患の治療 |
US20050163782A1 (en) * | 2003-06-27 | 2005-07-28 | Biogen Idec Ma Inc. | Modified binding molecules comprising connecting peptides |
DK3095793T3 (da) | 2003-07-28 | 2020-05-25 | Genentech Inc | Reducering af udvaskning af protein A under en protein A-affinitetskromatografi |
JP4969440B2 (ja) | 2004-04-08 | 2012-07-04 | デビッド, ビー. エイガス, | 疼痛治療のためのErbBアンタゴニスト |
EP2286844A3 (en) | 2004-06-01 | 2012-08-22 | Genentech, Inc. | Antibody-drug conjugates and methods |
SV2006002143A (es) | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
JP2008507520A (ja) | 2004-07-22 | 2008-03-13 | ジェネンテック・インコーポレーテッド | Her2抗体組成物 |
BRPI0515230A (pt) | 2004-08-19 | 2008-07-15 | Genentech Inc | polipeptìdeos, anticorpos e ácidos nucléicos isolados, composições, vetor de expressão, células hospedeiras isoladas, método para a produção de um anticorpo, artigos manufaturados, métodos de tratamento e para o alìvio de disfunções, métodos de produção e de seleção de um polipeptìdeo, anticorpo de ligação cd20 humanizado, anticorpo anti-her2 isolado e usos de um anticorpo |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
CA2587519A1 (en) | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
AU2005315912A1 (en) | 2004-12-13 | 2006-06-22 | F. Hoffmann-La Roche Ag | Novel pharmaceutical composition containing at least one Dolastatin 10 derivative |
TWI441646B (zh) | 2005-01-21 | 2014-06-21 | Genentech Inc | 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途 |
ES2440481T3 (es) | 2005-02-23 | 2014-01-29 | Genentech, Inc. | Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab |
TW200642695A (en) | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
US20070009976A1 (en) | 2005-07-06 | 2007-01-11 | Helmut Lenz | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody |
PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
CA2654584A1 (en) | 2006-06-05 | 2007-12-21 | Genentech, Inc. | Extending survival of cancer patients with elevated levels of egf or tgf-alpha |
US8015939B2 (en) | 2006-06-30 | 2011-09-13 | Asml Netherlands B.V. | Imprintable medium dispenser |
DK2056874T3 (da) | 2006-08-21 | 2012-10-15 | Hoffmann La Roche | Tumorterapi med et anti-vegf-antistof |
WO2008031531A1 (en) | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
WO2008109440A2 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her dimerisation inhibitor based on low her3 expression |
US8071097B2 (en) * | 2007-03-22 | 2011-12-06 | Genentech, Inc. | Apoptotic anti-IgE antibodies |
EP1997534A1 (en) | 2007-05-31 | 2008-12-03 | Pierre Fabre Medicament | Cancer treatment combination therapy comprising vinflunine and trastuzumab |
KR101169243B1 (ko) | 2007-06-06 | 2012-08-02 | 에프. 호프만-라 로슈 아게 | 종양 항원에 결합하는 비-표지된 제 1 단클론 항체 및 nir 형광 표지로 표지된 비-교차 반응성 제 2 단클론 항체로 이루어진 조성물 |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
ES2417148T3 (es) | 2007-06-08 | 2013-08-06 | Genentech, Inc. | Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2 |
KR20190140090A (ko) | 2007-07-09 | 2019-12-18 | 제넨테크, 인크. | 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지 |
AU2008298948B2 (en) | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
WO2009052249A1 (en) * | 2007-10-19 | 2009-04-23 | Genentech, Inc. | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
RU2498991C2 (ru) | 2007-10-30 | 2013-11-20 | Дженентек, Инк. | Очистка антител с помощью катионообменной хроматографии |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
EP2247310A4 (en) * | 2008-01-30 | 2012-06-27 | Abbott Lab | COMPOSITIONS AND METHODS FOR CRYSTALLIZING ANTIBODY FRAGMENTS |
AU2009221729A1 (en) | 2008-03-06 | 2009-09-11 | Genentech, Inc. | Combination therapy with c-met and HER antagonists |
EP2644204B1 (en) | 2008-03-18 | 2017-04-19 | Genentech, Inc. | Combinations of an Anti-HER2 antibody-drug conjugate and pertuzumab |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
FR2942799B1 (fr) * | 2009-03-06 | 2011-02-25 | Lfb Biotechnologies | Anticorps monoclonal anti-rhesus d |
EP2435071A1 (en) | 2009-05-29 | 2012-04-04 | F. Hoffmann-La Roche AG | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
SI2516469T1 (sl) * | 2009-12-22 | 2016-05-31 | Roche Glycart Ag | Protitelesa proti her3 in uporabe le-teh |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
CA2818669A1 (en) | 2010-12-09 | 2012-06-14 | Barbara Klencke | Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1 |
JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
SG194472A1 (en) * | 2011-01-28 | 2013-12-30 | Ca Nat Research Council | Engineering of immunoglobulin domains |
EP2683413A1 (en) | 2011-03-07 | 2014-01-15 | F.Hoffmann-La Roche Ag | In vivo selection of therapeutically active antibodies |
CN104334189A (zh) | 2011-10-14 | 2015-02-04 | 霍夫曼-拉罗奇有限公司 | Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品 |
EP2788500A1 (en) | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
US20130195851A1 (en) | 2011-12-23 | 2013-08-01 | Genentech, Inc. | Articles of manufacture and methods for co-administration of antibodies |
EP3545968A1 (en) | 2012-06-08 | 2019-10-02 | F. Hoffmann-La Roche AG | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
CA2889298C (en) | 2012-11-30 | 2024-01-02 | Anton Belousov | Identification of patients in need of pd-l1 inhibitor cotherapy |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
NZ751877A (en) | 2013-04-16 | 2020-04-24 | Genentech Inc | Pertuzumab variants and evaluation thereof |
CN112353943A (zh) | 2013-12-17 | 2021-02-12 | 豪夫迈·罗氏有限公司 | 用pd-1轴结合拮抗剂和紫杉烷治疗癌症的方法 |
-
2014
- 2014-04-15 NZ NZ751877A patent/NZ751877A/en unknown
- 2014-04-15 EP EP14723656.6A patent/EP2986643A2/en not_active Withdrawn
- 2014-04-15 PE PE2021000128A patent/PE20211214A1/es unknown
- 2014-04-15 RU RU2019115089A patent/RU2019115089A/ru unknown
- 2014-04-15 AU AU2014254086A patent/AU2014254086B2/en active Active
- 2014-04-15 SG SG10201911353WA patent/SG10201911353WA/en unknown
- 2014-04-15 CA CA2907776A patent/CA2907776C/en active Active
- 2014-04-15 CN CN201480020921.2A patent/CN105121471A/zh active Pending
- 2014-04-15 EP EP20201975.8A patent/EP3800204A1/en active Pending
- 2014-04-15 CA CA3071678A patent/CA3071678A1/en not_active Abandoned
- 2014-04-15 US US14/253,038 patent/US9815904B2/en active Active
- 2014-04-15 NZ NZ712012A patent/NZ712012A/en unknown
- 2014-04-15 KR KR1020207019835A patent/KR20200085942A/ko not_active Application Discontinuation
- 2014-04-15 KR KR1020157032283A patent/KR20150143649A/ko active Application Filing
- 2014-04-15 WO PCT/US2014/034200 patent/WO2014172371A2/en active Application Filing
- 2014-04-15 RU RU2015141520A patent/RU2737727C2/ru active
- 2014-04-15 EA EA201591643A patent/EA201591643A1/ru unknown
- 2014-04-15 AR ARP140101600A patent/AR095863A1/es unknown
- 2014-04-15 BR BR112015024926A patent/BR112015024926A2/pt active Search and Examination
- 2014-04-15 JP JP2016509031A patent/JP2016522176A/ja not_active Withdrawn
- 2014-04-15 MA MA38567A patent/MA38567A1/fr unknown
- 2014-04-15 SG SG11201508536PA patent/SG11201508536PA/en unknown
- 2014-04-15 PE PE2015002163A patent/PE20151769A1/es unknown
- 2014-04-15 SG SG10201706045RA patent/SG10201706045RA/en unknown
- 2014-04-15 MX MX2015013898A patent/MX368259B/es active IP Right Grant
- 2014-04-15 MY MYPI2015002532A patent/MY173295A/en unknown
- 2014-04-15 TW TW103113741A patent/TWI554284B/zh active
-
2015
- 2015-09-03 IL IL241103A patent/IL241103B/en active IP Right Grant
- 2015-09-07 ZA ZA2015/06594A patent/ZA201506594B/en unknown
- 2015-10-01 MX MX2019005151A patent/MX2019005151A/es unknown
- 2015-10-14 PH PH12015502382A patent/PH12015502382A1/en unknown
- 2015-10-15 CL CL2015003049A patent/CL2015003049A1/es unknown
- 2015-10-15 CR CR20150576A patent/CR20150576A/es unknown
- 2015-12-24 HK HK15112673.2A patent/HK1211948A1/xx unknown
-
2017
- 2017-09-28 CL CL2017002445A patent/CL2017002445A1/es unknown
- 2017-10-19 US US15/788,632 patent/US20180037662A1/en not_active Abandoned
- 2017-10-19 US US15/788,598 patent/US20180037661A1/en not_active Abandoned
- 2017-10-19 US US15/788,574 patent/US9969811B2/en active Active
-
2018
- 2018-10-05 AU AU2018241141A patent/AU2018241141B2/en active Active
-
2019
- 2019-07-12 US US16/510,287 patent/US20190345258A1/en not_active Abandoned
- 2019-07-12 JP JP2019129841A patent/JP2020015719A/ja active Pending
- 2019-08-06 US US16/533,488 patent/US20200157238A1/en not_active Abandoned
- 2019-08-08 CL CL2019002244A patent/CL2019002244A1/es unknown
- 2019-10-22 AU AU2019253804A patent/AU2019253804A1/en not_active Abandoned
-
2020
- 2020-06-15 IL IL275398A patent/IL275398A/en unknown
-
2022
- 2022-06-27 US US17/809,098 patent/US20230047103A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019002244A1 (es) | Variantes de pertuzumab y su evaluación. (divisional solicitud 201702445) | |
CY1120529T1 (el) | Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων | |
CY1121849T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου | |
BR112018075140A2 (pt) | composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8 | |
UY36705A (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
CR20170425A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
UY35661A (es) | Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que lo s contienen | |
CR20150247A (es) | Anticuerpos de antihemaglutinina y métodos de uso | |
BR112016008644A2 (pt) | Inibidor de dinamina 2 para uso no tratamento de uma miopatia centronuclear; método para identificar ou triar moléculas úteis no tratamento de uma miopatia centronuclear, de preferência, xlcnm; e composição farmacêutica | |
BR112015023026A2 (pt) | indicador de esterilização para esterilizantes oxidativos e processo para determinar a eficácia de um processo de esterilização utilizando esterilizantes oxidativos | |
EA202191513A1 (ru) | Снижение вязкости фармацевтических составов | |
CL2015003019A1 (es) | Derivados biaromáticos antibacterianos | |
UY35305A (es) | Compuestos sustituidos como moduladores de la pro teína de activación de la 5-lipoxigenasa (flap) | |
BR112016016853A2 (pt) | Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso | |
BR112017009792A2 (pt) | anticorpos anti-pdgf-b e métodos de uso | |
PE20151142A1 (es) | Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina | |
CR20160448A (es) | Nuevos derivados de piridina | |
CO2017001601A2 (es) | Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio | |
UY34166A (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib | |
ECSP13013075A (es) | Método de tratamiento de la fiebre dengue | |
CO2019009020A2 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
UY34552A (es) | Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen | |
BR112015005268A2 (pt) | seringa contendo uma composição, em particular farmacêutica, composta por imunoglobulinas, seu método de fabricação e respectivo uso | |
UY35004A (es) | Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen | |
DE102013218545B8 (de) | Vorrichtung zur Herstellung von Verpackungseinheiten |